Maravai Lifesciences Holdings (MRVI) Profit After Tax (2020 - 2026)

Maravai Lifesciences Holdings' Profit After Tax history runs 7 years deep, the most recent figure standing at -$6.4 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 78.7% year-over-year to -$6.4 million in Q1 2026; TTM through Mar 2026 was -$84.3 million, a 64.6% increase from a year earlier, with the FY2025 full-year figure at -$130.8 million, up 9.72% from the prior year.
• Profit After Tax eased to -$6.4 million in Q1 2026 per MRVI's latest filing, from $37.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $308.1 million in Q4 2022 and bottomed at -$172.5 million in Q3 2024.
• The 5-year median for Profit After Tax is -$11.9 million (2023), against an average of $1.0 million.
• Across the five-year window, Profit After Tax tumbled 1041.93% in 2024 and surged 242.73% in 2025, its largest moves.
• Year by year, Profit After Tax stood at $308.1 million in 2022, then tumbled by 135.7% to -$110.0 million in 2023, then jumped by 76.45% to -$25.9 million in 2024, then jumped by 242.73% to $37.0 million in 2025, then sank by 117.25% to -$6.4 million in 2026.
• Per Business Quant, the three latest MRVI Profit After Tax figures stand at -$6.4 million (Q1 2026), $37.0 million (Q4 2025), and -$45.1 million (Q3 2025).